GlassScriptPhysician profile
Patricia A Wallace
NPI 1629162995
$2,785.94
in general payments reported to CMS, 2019-2025
26 companies · $277 in 2025
The $277 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $260 · 2021: $551 · 2022: $550 · 2023: $437 · 2024: $230 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $784.84 | 2019-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $244.54 | 2021-2025 | Botox |
| Caldera Medical, INC | $237.54 | 2022-2023 | Desara |
| Therapeuticsmd, INC. | $221.38 | 2019-2022 | |
| Hologic Sales and Service, LLC | $172.33 | 2019-2025 | Aptima |
| Hollister Incorporated | $157.22 | 2021-2023 | Infyna Chic |
| Allergan, INC. | $139.46 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $108.36 | 2024-2025 | Gemtesa |
| Medtronic, INC. | $90.68 | 2023-2025 | Altaviva, Interstim |
| Acella Pharmaceuticals, LLC | $86.06 | 2024-2025 | NP Thyroid 60 |
| Vertical Pharmaceuticals, LLC | $81.61 | 2019 | |
| Mayne Pharma Commercial LLC | $74.20 | 2021-2025 | |
| Urovant Sciences INC | $51.46 | 2022 | |
| Abc Home Medical Supply, INC. | $46.98 | 2022 | |
| Coloplast Corp | $42.38 | 2019-2023 | Altis |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $42.36 | 2019 | |
| Ascend Therapeutics US, LLC | $38.71 | 2020-2023 | |
| Medtronic USA, INC. | $27.82 | 2020 | |
| Aspira Women'S Health INC | $24.99 | 2024 | Ova1 |
| Millicent US INC | $24.35 | 2024 | Femring, Intrarosa |
| Minerva Surgical, INC | $16.09 | 2019 | |
| Myovant Sciences INC. | $15.63 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.53 | 2019 | |
| Pfizer INC. | $14.59 | 2019 | |
| Electronic Waveform Lab, INC. | $13.51 | 2020 | |
| Avion Pharmaceuticals | $13.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.